Who are Gemini Therapeutics's investors?

Gemini Therapeutics's investors include Altium Capital, Lightstone Ventures, Atlas Venture, OrbiMed.

How much funding has Gemini Therapeutics raised?

Gemini Therapeutics has disclosed $2M raised across 1 of its 2 known rounds.

Where is Gemini Therapeutics headquartered?

Gemini Therapeutics is headquartered in Cambridge, US.

Gemini Therapeutics

Cambridge, US · Founded 2015 · Delaware corporation · 4 known investors

Find your way into Gemini Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Gemini Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.

Biotech

Founders & leadership

James McLaughlin President and CEO, Co-Founder2015–2019James McLaughlin founded Gemini Therapeutics, a precision medicine company addressing age-related macular degeneration, which he grew through R&D, financing, and team building before co-founding Saturn Therapeutics. He previously co-founded Voyager Therapeutics, a CNS-focused gene therapy company where he led operations, and worked as a biotechnology investor at Third Rock Ventures and Advanced Technology Ventures; he holds an MBA from Harvard Business School and a BA from Colby College.

Board

Jean GeorgeBoard directorManaging Partner at Lightstone Ventures

Jason Rhodes Board directorPartner at Atlas Venture

Carl Gordon Board directorManaging Partner at OrbiMed

Investors · 4

Altium Capitallisted by Altium CapitalNew York

How we know: Altium Capital's portfolio page · Not right? Tell us

Lightstone Ventureslisted by Lightstone VenturesPortola Valley

How we know: Lightstone Ventures's portfolio page · funding news · medcitynews.com · Not right? Tell us

Atlas VenturereportedCambridge · $500K – $1M

How we know: a partner's Signal profile · funding news · medcitynews.com · Not right? Tell us

OrbiMedreportedNew York · $1M – $75Mvia Carl Gordon · board

How we know: board seat on SEC Form D · funding news · medcitynews.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$2M disclosed across 1 of 2 rounds · 2016–2017

Undisclosed amountSeries AOct 2017
Atlas Venture (lead), Lightstone Ventures (lead), OrbiMed (lead)
Source ↗

▶$2MraisedMay 2016 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Jean GeorgeDirector
James McLaughlinExecutive Officer, Director
Jason RhodesDirector
Carl GordonDirector

Offering amount: $2M
Amount sold: $2M
First sale: Apr 2016
Incorporated: Corporation, Delaware, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Gemini Therapeutics went on to found or lead other companies.

Jason RhodesDirectorFounded Rectifypharma +1 Diego ReyChief Executive OfficerFounded Endpoint Health

In the news

Gemini Therapeutics and Avitide Enter Into Exclusive License Agreementprnewswire.com · Dec 2019

Frequently asked questions

What does Gemini Therapeutics do?: Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.
Who are Gemini Therapeutics's investors?: Gemini Therapeutics's investors include Altium Capital, Lightstone Ventures, Atlas Venture, OrbiMed.
How much funding has Gemini Therapeutics raised?: Gemini Therapeutics has disclosed $2M raised across 1 of its 2 known rounds.
Where is Gemini Therapeutics headquartered?: Gemini Therapeutics is headquartered in Cambridge, US.